If facial changes during GLP-1 treatment have you considering Botox, tell the clinician what changed.

Ask which product is proposed

The US BOTOX Cosmetic label includes temporary improvement of moderate-to-severe frown lines, crow's feet and forehead lines associated with muscle activity in adults. Ask which indication fits your concern. Those indications are not evidence of GLP-1-specific facial recovery. [2]

Bring the treatment history

AAD recommends sharing all medicines, herbs, vitamins and minerals, plus earlier surgery and cosmetic treatments. Include your GLP-1 prescription. Its consultation questions cover expected results, complications, cost and who will inject. [3]

AAD recommends a board-certified dermatologist or that doctor's medical staff; if staff give the injections, the dermatologist should be in the office and immediately available. Ask how the clinic meets that recommendation. [3]

Discuss risks and the warning

The BOTOX Cosmetic label warns that toxin effects can spread beyond the injection area, with symptoms reported hours to weeks later. Seek immediate medical care for breathing, speech or swallowing difficulties. The label also states there are no definitive serious distant-spread reports associated with labeled upper-face cosmetic doses. That does not guarantee an individual outcome. [2]

Get the aftercare instructions

AAD's FAQ advises against rubbing or massaging treated areas. Ask for written aftercare and whom to contact with concerns. Confirm the expected duration before budgeting for repeat visits. [1]

These are US guidance and labeling, not GLP-1-specific cosmetic trials. If your concern is facial fullness, read our filler consultation guide.

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.

Sources

  1. Botulinum toxin therapy: FAQsAmerican Academy of Dermatology↩ Back to text
  2. BOTOX Cosmetic US prescribing information, revised October 2024AbbVie↩ Back to text
  3. Botulinum toxin therapy: PreparationAmerican Academy of Dermatology↩ Back to text